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1. Abstract 
 
Borna Disease is a severe, immunopathological disorder of the central nervous 
system, caused by infection with Borna Disease Virus. The main known naturally 
affected animal species are horses and sheep in endemic areas in central Europe. The 
detection of BDV in these hosts is achieved by histological, immunohistochemical 
and serological approaches and/or PCR-based technologies. 
In this study, the effect of some proteins and drugs in vitro on two BDV infected cell 
lines (MDCK and Vero cells) was tested. The method is based on an enumeration of 
the infected cells, labelled with immunofluorescence compounds. 
A tracking method using a fluorescent cell marker (CMTPX) was developed, in order 
to find out if the reduction of the number of infected cells was due to a cytostatic 
effect or to an impairment of the virus spread from cell to cell.  
This cell tracker enables, by a double staining technique, to appreciate at the same 
time the BDV infected cells and the cell lineage. The results obtained show that 
Ribavirin and Cytosine β-D-arabinofuranoside have an inhibitory effect on BDV in 
culture, whereas Amantadine had no consistent effect on BDV replication in vitro. 
The effect of Ribavirin was mainly directed to inhibit the virus spread through the 
cell contact, while Cytosine β-D-arabinofuranoside inhibited at the same time the 
replication of infected cells as well as the virus passage from cell to cell. 
None of the proteins tested, having antiviral effects against other viruses, presented 
antiviral activity against BDV. 
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2. Introduction on Borna Disease Virus (BDV) 
 
 
2.1 History 
 
Borna Disease (BD) is a unique neurological disease caused by infection with an 
RNA virus, Borna Disease Virus (BDV).  The oldest report describing the typical 
characteristics of BD are found in 1660, speaking of pain which pushes the horses or 
makes them dull and dumb [47]. 
A veterinary handbook published in 1785 [2, 85] contained an accurate report of the 
clinical syndrome, implicating unsatisfied sexual desires or overfeeding in its 
pathogenesis and suggested colourful therapies such as phlebotomy, plucking air 
from selected locations, and threading a rope coated Spanish fly cream through the 
subcutaneous tissue of the infected horses [79]. 
The disease was first described in details approximately 200 years ago in horses in 
southeastern Germany as a syndrome of agitated aggressive behaviour that progressed 
over a period of weeks to inanition and death [2, 85]. 
The disease became more important in 1885, when a large number of horses died in 
the town of Borna (Saxony, Germany), during an epidemic outburst of BDV-induced 
disease [115, 129]. After this time point, the name of Borna Disease was adopted and 
in 1896 for the first time, the definition of Borna Disease appeared on the official 
veterinary review in Berlin (Berliner Thierärztliche Wochenzeitschrift) referred to a 
cerebrospinal meningitis in horses [76]. 
In 1909, Joest and Degen discovered intranuclear inclusion bodies associated with the 
disease in the ganglion cells of the Hippocampus, and for the first time a post mortem 
diagnosis of the BD was possible [71]. 
The nature of the causing virus had remained obscure until the etiology of BD was 
established in 1925, when Zwick and Seifried proved its transmissibility [148]. 
In recent years, the number of animals diagnosed with classical BD in Europe was 
relatively low, usually affecting fewer than a total of 100 horses and 100 sheep every 
years [26, 39, 63, 129] . 
To our knowledge, until recently, no confirmed cases of BD had been reported in 
horses or sheep outside the endemic areas, that other than certain areas of Germany 
[39], also includes part of the upper Rhine valley between Switzerland, Austria and 
the Principality of Liechtenstein [24, 129, 143] . 
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However, this apparent geographic restriction may reflect lack of reliable methods 
and reagents for diagnosis of the infection or insufficient disease awareness. 
Recently, the interest in BDV has increased because it has been recognized that that 
geographic distribution of the natural infection and the host range spectrum are much 
larger than previously appreciated [79], including sheep, cattle, cats and even human 
in other parts of Europe as well as in North America and Asia [85]. 
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2.2 Aetiology 
 
Borna Disease Virus represents the only member of the family Bornaviridae that is 
part of the order Mononegavirales, which includes the families of Filoviridae, 
Paramyxoviridae and Rhabdoviridae, BDV is an enveloped, non-segmented, single- 
and negative-stranded RNA virus (NNS RNA) [146]. There are four known BDV-
strains, called Borna V, Borna HE/80, Borna No/98, Borna H1766; the genomes of 
these strains have been sequenced and showed a very high sequence conservation, 
which is uncommon for RNA virus [22, 29, 65, 100, 108]. 
A characteristic of the BDV is that its replication and transcription of the genome 
occur in the cell nucleus: the only other negative-strand RNA virus know to 
transcribe in the cell nucleus is influenza virus [85]. The genome size is about 8.9 kilo 
bases, and the organization of the six major ORFs is similar to that of the others 
Mononegaviruses [123]. 
Electron microscopic studies of negative-stained cell-free BDV infectious particles 
have shown a spherical morphology with a diameter ranging from 70 to 130 nm [50, 
77, 146]. These particles contain an internal electron-dense core (50 to 60 nm) and a 
limiting outer membrane envelope, which appeared to be covered with spikes 
approximately 7.0 nm long [77, 121]. 
Virus infectivity is rapidly lost at temperatures higher than 56°C, as well as at pH’s 
below 5 and above 12, and by treatment with organic solvents, detergents, 
formaldehyde and exposure to ultra violet radiation [33, 121]. 
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2.3 Epidemiology 
 
2.3.1 BDV in animals 
 
BDV infections mainly affect horses and sheep but the disease involves also other 
animals, although the incidence appears to be very low. BDV was found in donkeys 
[24, 147], goats [24] and cattle [17, 25] with neurological disease and prominent 
mononuclear infiltration of the CNS. It has also been suggested as agent of the 
‘staggering disease’ in cats [87], but its effective involvement in these cases is still 
matter of discussion. BDV was also identified in lynx [12], rabbits [92], ostriches [5, 
89], tree-shrews [128] and in many laboratory animals, such as rats, mice, rabbits and 
gerbils [79, 121].  
Specific BDV-antibodies were detected in horses’ sera from Holland, Luxemburg, 
Poland, Russia, Israel [61], Japan [95] and USA [73], but in none of these cases 
clinical signs of the disease were present. These reports of asymptomatic natural 
infection of animals suggest that the virus may be even more widespread than 
previously thought [125]. 
It has been assumed that a possible way of infection can be the transmission of BDV 
through body secretions (mainly urine and faeces, but also salival, nasal or 
conjunctival secretions). In fact, several studies detected BDV RNA in body 
secretions. [8, 63, 114, 116] 
A direct contact with these secretions or exposure to contaminated food or water is 
regarded a successful way of transmission [114, 120].  
The natural source of infection has still not been determined [129]. Anyway, rodents 
are considered  potential reservoir and vector, because it has been demonstrated that 
the urine of experimentally infected rats contain high BDV titers, and inoculation of 
adult black hooded rats with BDV induce persistent infection [59]. Nevertheless, their 
rule in the Borna epidemiology has not yet been demonstrated. 
Very recently, shrews have been recognized as vectors [64]. 
Other wild species reported that could be implicated in the BDV epidemiological 
cycle are wild birds [13, 31] and ticks [121]. 
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2.3.2 BDV and zoonotic potential 
 
It has been suggested that BDV infection might contribute somehow to the syndrome 
of major depressive illness by altering neuronal cells in the limbic system [18]. 
Behavioural abnormalities and disturbance have been observed in infected rats. The 
behaviour disturbances were considered to be reminiscent of affective disorders such 
as bipolar and monopolar. This observations led to the question whether human 
patients with similar disorders might be infected with BDV [85]. Representative 
longitudinal studies showed that episodes of depressive illness in humans as well as 
apathetic phases in infected horses were accompanied by BDV-protein expression 
and followed a similar clinical course [19]. Seroepidemiologic studies have 
demonstrated BDV-specific antibodies in sera of psychiatric and neurological patients 
in Germany, Japan and the United States [21, 44]. Others studies [119] showed a 
significantly higher prevalence of BDV serum antibodies among hospitalized 
psychiatric patients and a moderately higher seroprevalence among neurologic 
patients than among controls. Investigations of CSF’s of BDV-seropositive patients 
acutely ill with psychiatric disorders (mainly schizophrenia and affective psychosis) 
showed intrathecally synthesized anti BDV- specific immunoglobulin (IgG) in 25% 
of the patients [115]. Also the chronic fatigue syndrome has been related with a 
possible BDV infection [96]. 
A slightly higher level of seroprevalence was found among psychiatric patients in an 
area with high incidence of natural BDV in horses (South of Germany) [115]. 
In the last years, evidence of human infection of BDV has been sufficiently 
confirmed, but a causal link with neurological diseases remains difficult to prove 
[65]. In fact, the etiopathogenic relationship between virus and human disease 
remains a major question [20, 85, 140]. 
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2.4 Clinical manifestation in animals 
 
Clinical symptoms exhibited by horses and sheep with BDV are quite variable and 
can vary from behavioural anomalies to severe neurological disorder and death, 
paralleling to the severity of the inflammatory reaction in the CNS. They are species, 
age and immune status dependent [23, 118] .  
The incubation period is also noticeably different. It can range from 2 weeks to few 
months and BDV infections in horses can also be clinically inappearent [121]. 
Spontaneous BD in horses and sheep typically begins with a short prodromal stage of 
depression and anorexia. This is followed by overt disease, the hallmarks of which are 
somnolence, ataxia, dysphagia and multiple neuronal degeneration. Other non 
specific symptoms are hyperthermia, colic and constipation, or typical signs of 
encephalitis (with movement and posture disturbances, proprioceptive deficits, 
lethargy, hyperexcitability). The course of the disease is progressive over 1 to 3 
weeks and usually leads to death [23, 40, 53, 113].   
The reported mortality rate is about 80-100% in horses and about 50% in sheep [115]. 
In experimental infections of laboratory animals all the clinical manifestations and the 
incubation period appear to depend on the animal species, viral strain and host 
immune status [31]. 
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2.5 Immunopathogenesis 
 
BD is defined as a non purulent polioencephalomyelitis caused by a T cell-dependent 
immune mechanism [32]. 
BDV is a highly neurotropic agent. It gains access to the CNS after a receptor-
mediated endocytosis [49], probably by intraaxonal migration through the olfactory 
nerve, the olfactory neuroepithelium or nerve endings in the oropharyngeal and 
intestinal regions [118]. Virus spreads throughout the CNS by intraaxonal transport 
and centrifugally into the peripherals nerves. Antibody titres in naturally infected 
animals are relatively low and are found in sera and cerebrospinal fluid. Whether 
BDV-specific antibodies are neutralizing is not certain [86, 97].  
In immunocompetent laboratory animals, as shown in extensive studies on the Lewis 
rat, no infectivity was found in extraneural tissue at any stage of infection, while in 
newborn animals the virus spread is throughout the whole organism [97]. 
Despite productive virus replication in the CNS, immunocompromised and newborn 
animals do not become ill with BD or encephalitis, suggesting the hypothesis of a 
virus-induced cell-mediated immunopathological basis of BD. In fact, T cells play an 
important role in the immunopathological reaction and in the set on of the disease 
[115]. 
In experimentally infected rats, the cellular mediated immune reaction has been 
characterized by perivascular infiltration of CD4 positive and CD8 positive T cells 
(CD4 positive cells are prominent), with presence of natural killer cells and 
macrophages [132]. 
The same pattern of lymphocyte phenotypes has been observed in horses and sheep. 
In brief, the majority of inflammatory cells in perivascular infiltrates as well as in 
parenchymal and meningeal infiltrates were CD3 positive. CD4 positive cells 
outnumbered CD8 positive cells in perivascular infiltrates as well as in the 
parenchyma. Macrophages were seen less often and B-cells or plasma cells were 
demonstrated at lower numbers [23].  
Other studies confirmed that BD in rats appears to be a CD4 positive T-cell 
dependent immunopathological disease, in which CD8 positive T-cells and /or CD8 
positive T-cell- mediated cytodestructive mechanism lead to tissue damage [91], 
brain atrophy and clinically to organ dysfunction and manifested disease [121, 130]. 
 11
2.5 Diagnosis  
 
A definitive clinical or intra vitam diagnosis of BD is not possible yet, even if 
meningoencephalitis induces, in the acute phase, a slight alteration of protein 
concentrations in cerebrospinal fluid. These indicators are not specific for BD but are 
indicators of viral meningoencephalitis [15, 121]. 
Serological diagnosis can be applied to living animals by antibody detections in blood 
and/or CFS. Western blot [63], ELISA [40] and immunofluorescence assay (IFA) 
[62] can be used to confirm a diagnosis and the latter method is commonly considered 
the most reliable [31]. However, it has been proved that antibodies could not be 
regularly found in animals where the diagnosis of BD was histologically confirmed 
[24]. 
On the histopathological level, various degrees of encephalitis can be observed. 
Typically, BD is characterised by disseminated mononuclear meningitis and 
poliencephalomyelitis with subsequent neuronal degeneration. Usually, a site 
predilection for areas of the limbic system, particularly the hippocampal formation 
can be noted, whereas the brain stem and cerebellum are relatively spared [23]. 
Joest-Degen inclusions bodies in nuclei of infected neurons have been used as BDV-
specific markers, but they are not always observed [31, 52]. 
Viral isolation from brain tissue is a non reliable method, due to the low number of 
infectious particles in vivo [58, 129]. In vitro, BDV can be easily cultivated on Vero 
cells (monkey kidney cells) and MDCK (dog kidney cells). BDV persistently infected 
cells do not show any cytopathic effect [31]. 
RT-PCR or RT-nested-PCR [83] can be used for demonstrations of viral RNA from 
brain or blood sample. This is a very sensitive technique, but prone to cross-
contamination between sample as well as laboratory contamination. Moreover, it is 
not possible to detect variant strains that have altered sequences in the target gene 
[31]. 
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2.7 Antiviral substances and treatment  
 
To date little is known about antiviral substances that may inhibit the replication of 
BDV, thus there is no effective treatment of BD. Different compounds have been 
investigated against BDV. It has been shown that high concentration of Ribavirin 
strongly inhibited replication of BDV in persistently infected MDCK cells [93] and 
the nucleoside analog 1-β-D-arabinofuranosylcytosine (or Cytosine β-D-
arabinofuranoside, CAF) efficiently inhibits BDV replication [7]. Furthermore, 
Amantadine sulfate has been reported to inhibit BDV replication in persistently 
infected human cells in culture as well as in a psychiatric patient [16]. However, this 
inhibitory effect of Amantadine toward BDV could not be confirmed by other studies 
[28, 55, 131]. 
A mannose derivative, 1B6TM has been proved to prevent de novo infection with 
BDV of cultured human oligodendroglial cells [134]. Interferon antiviral activity 
against BDV has been demonstrated in some cell lines [54]. The immuno-supressive 
drug cyclosporine A was also able to prevent BD in experimentally infected 
laboratory animals [133]. 
 
 
 
2.7.1 α-D-Mannose 
 
α-D-Mannose occupies the terminal position on the N-linked carbohydrate side chain 
of BDV-specific gp17 [135]. A hydrophobic derivative of this sugar residue, the 1-0-
benzyl-6-0-trityl-α-D-mannopyranoside (1B6TM), showed a potent and a selective 
inhibition of BDV replication in vitro without any cytotoxic effect. Because BDV 
particles contain terminal α-D-mannose residues the antiviral effect of 1B6TM is 
likely to be highly specific to those viruses in which such terminal carbohydrates are 
essential for the infection process [134]. 
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 2.7.2 Interferon 
 
  Interferon-α/β (INF) is a natural antiviral agent, synthetized in response to most viral 
infections by a large number of vertebrate cells [34].  A previous work showed that 
exposure of primary rabbit brain cells to exogenous INF prevented their infection 
with BDV, while IFN treatment caused no inhibitory effect on BDV persistently 
infected rat lung cells [142]. It remained unclear, however, whether the poor 
performance of INF in persistently infected cells indicated that early steps of the 
BDV replication cycle were the exclusive targets of this antiviral cytokine. A later 
study has shown that IFN can strongly reduce the virus load in persistently infected 
monkey Vero cells but not in rat C6 cells. That indicates that steps of the BDV 
replication cycle of virus entry are affected in IFN- responsive cell lines [54]. Unlike 
all other cells line were tested, C6 cells could also not be protected with IFN from de 
novo infection with BDV, indicating that it lacks at least one component of the IFN 
system that inhibits BDV. From these last results, it cannot be excluded that IFN 
plays a role during the spread of the virus to the CNS after natural infections with 
BDV via peripheral nerves [54]. 
 
 
2.7.3 Cyclosporine A 
 
As already mentioned, in rats persistently infected with BDV, severe neurologic 
disorders and occasional death are the consequence of a T cell-mediated 
immunopathologic reaction in the brain. It has been proved that the pathologic 
alterations in the brain and, as a result, BD can be prevented by treatment with the 
immunosuppressive drug cyclosporine A (CSA) [133]. CSA is an immunosuppressive 
agent that has been proved very useful also in the treatment of experimental disease 
caused by immune mechanism [122]. In experimental models, the onset of the disease 
has been clearly shown to coincide with histologic alteration 15 to 28 days after 
intracerebral infection of rats. After immunosuppression with CSA, infected rats 
developed a persistent infection yielding comparable titers of infectious virus in 
neural tissue as compared to nontreated BDV infected animals. However, such 
immunoincompetent rats show no clinical symptoms or lymphocytic infiltrations 
despite the presence of virus in the brain [60].  
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 2.7.4 Ribavirin, CAF and Amantadine 
 
The antiviral effectiveness and the action mechanism of Ribavirin, CAF and 
Amantadine are discussed later in details (see 2.9.1-2.9.3). 
 
 
2.7.5 Liquor filtration 
 
An alternative adjuvant therapy that has been tested in the last years is the liquor 
filtration [10, 11]. It has been described as an experimental method in human patients 
affected from therapy-resistant schizophrenia, psychoses and in diseases where an 
immunopathogenetic genesis was recognised, like in BD [9]. 
From previous studies, an earlier unknown therapeutic effect of a cerebrospinal fluid 
filtration (CSFF) in therapy-resistant major depression has been suggested for different 
reasons: firstly, therapy-resistant major depression and comorbid symptoms improved 
with CSFF; secondly, test performance improved with CSFF; lastly, relapse occurred 
after discontinuation of medication but therapeutic effects were repeated with a second 
CSFF serie [9].  
The rationale for a CSFF was in short: therapy resistance, symptom characteristics, 
BDV serum and/or cerebrospinal fluid antibodies, known immune pathogenesis of 
BD. The first schizophrenic patient submitted to this procedure, improved with CSFF 
and was clinically stable, since 2.5 years free of medication, fully working and socially 
integrated, himself feeling healthy [9]. 
However, the exact mode of action of CFSS remains elusive. Filtering out toxic or 
blocking factors may explain a rapid short-lived but not lasting improvement. It has 
been speculated whether removing one endocaine may help to normalize 
immunological function within the central nervous system [9].  
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2.8 Antiviral Proteins 
 
Since the 1950s, drugs capable of inhibiting virus replication were described in the 
scientific literature, but most of these antiviral chemotherapeutic agents are 
characterized by limited efficacy, adverse side effects and suboptimal 
pharmacokinetics [103]. Recent technology advances have facilitated greater 
understanding of the molecular biology and biochemistry of the viral enzymes 
involved in the viral life cycle. In particular, viral enzymes which are essential for the 
production of infectious virus represent potential therapeutic targets. 
During the last decade, preclinical research efforts have centred on virus encoded 
proteases as potential targets for antiviral intervention [36, 74, 80, 103]. 
Proteins or modified proteins have also been reported to possess antiviral activity 
[102]. In our investigations, we decided to test against BDV proteins that were shown 
to have in previous studies a marked antiviral activity against several viruses like 
Human Herpes Simplex Virus type 1 [101], HIV and Human Cytomegalovirus [56] 
and Adenovirus [4]. 
 
 
2.8.1 Bovine lactoferrin  
 
Bovine lactoferrin has been recognised as a potent inhibitor towards different 
enveloped viruses such as Herpes Simplex Virus (HSV) 1 and 2 [57], Human 
Cytomegalovirus [56], Human Immunodeficiency Virus [112, 139], Human Hepatitis 
C Virus [67, 145], Respiratory Syncytial Virus [110] and Hantavirus [94]. Moreover, 
its antiviral activity against two naked viruses, SA-rotavirus and Poliovirus type 1, 
has been also demonstrated [90, 136]. For all the investigated viruses, lactoferrin 
exerted its antiviral activity in the early phases of infection. Since lactoferrin is 
known to bind cell surface gycosaminoglycans and low-density lipoprotein receptors, 
which acts as binding sites for HSV 1 and HIV [117, 124], its inhibiting activity on 
these viruses has been ascribed to a competition for cell receptors. However,  even 
thought a direct interaction between lactoferrin and viral particles has not been ruled 
out till now. For Rotavirus and Poliovirus, which interact with carbohydrate moieties 
other than glycosaminoglycans, it has been suggested that lactoferrin could bind to 
viral particles, in a similar manner as it has been reported for some enveloped viruses 
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[139, 145]. Interestingly, a further effect on a later intracellular step of virus infection 
has been also described in Rotavirus infection [137]. 
 
2.8.2 β-lactoglobulin 
 
β-lactoglobulin has shown to possess inhibitory effect in vitro against several 
viruses like Herpesvirus [99] and HIV [14, 98]. 
Several studies have shown that acylated plasma and milk proteins with increased 
negative charge have a potent antiviral activity, in particular against HIV-virus 
[138]. The antiviral effect seems to be positively correlated with the number of 
negative charges introduced into the various polypeptides: in fact, proteins with a 
high content of basic amino acids in which all of the available epsilonNH2 groups 
were anionized yielded the strongest antiviral activity [138]. The mechanism of 
action of acylated proteins and β-lactoglobulin consists to block the fusion process 
between the cell membrane and the virus [138]. 
 
 
2.8.3 Bovine serum albumin 
 
Bovine serum albumin has been demonstrated to improve the cytoplasmatic 
delivery of a phosphodiester oligonucleotide (PO) positively influencing at the 
same time the antiviral activity in vitro against Human Cytomegalovirus [3]. 
Human serum albumin has been investigated as well [69]. Its modification by 
introduction of a single or two carboxylic groups (Suc-HSA and Aco-HSA) yielded 
strongly negative charged compounds. In studies against HIV-1 virus, it has been 
demonstrated that the mechanism of action is an inhibition of a post-binding virus-
cell fusion, probably due to interference with the gp41-mediated fusion process. 
Moreover, Aco-HSA was also able to inhibit virus-cell binding by shielding viral 
gp120 [69]. 
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2.8.4 Lysozyme 
 
Lysozyme is widely known to have both bactericidal and antiviral activity. It has 
been proved to inhibit DNA and RNA synthesis, to damage the outer membrane of 
E. coli [106]. The block of macromolecular synthesis and permeabilization of the 
inner membrane impair the stability of the microorganism and lead to bacterial 
death. Lysozyme exerts a membrane disturbing activity on fungal and plant cells as 
well [38]. Moreover, it inhibits the formation of syncytia in cell monolayer infected 
with Herpes Simplex Virus [27]. 
On the other hand, lysozyme has already been found strongly toxic for the Vero 
cells [102], toxicity  has been confirmed in this study on MDCK cells. 
 
 
2.8.5 α-lactalbumin 
 
Also α-lactalbumin (together with β-lactoglobulin) both native and after 
modification with 3-HP (see 2.8.6), have been tested against HIV-1 [14]. The 
introduction of multiple negatively charged carboxyl groups along the polypeptide 
backbone leads to repulsion within the protein molecule and this is likely to affect 
the specific tertiary, and perhaps also secondary structure of the protein.  
One of the most potent inhibition of HIV-1 replication was obtained from 3-HP α-
lactalbumin. This compound showed a low cytotoxicity [14].  
 
 
2.8.6 Chemical modification of the proteins 
 
3-Hydroxypthalic anhydride (3-HP) is an aromatic anhydride that reacts with the 
terminal NH3-group of lysin. Through this reaction, hydrophobic and negatively 
charged groups are introduced in the lysine molecule and consequently in proteins 
[3, 14, 78, 101, 138]. Chemical modification of β-lactoglobulin through reaction 
with 3-HP yield a compound strongly active against HIV [98], Herpes Simplex 
Virus-1 and –2 [99] and Chlamydia trachomatis [70]. 
More in general, some 3-HP-modified proteins strongly inhibit the multiplication of 
Herpes Simplex Virus-1 and this confirmed that the introduction of hydrophobic 
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and negatively charged residues in the polypeptide chain could be a useful 
procedure to confer antiviral activity to a protein [101].  
Negative charge and hydrophobic interaction between antiviral compounds and 
virus envelope proteins have been suggested as a possible active principle for this 
antiviral activity [99]. 
However, the fact that 3-HP-modified proteins failed to inhibit, beside BDV also 
Bovine Parainfluenza Virus type 3 and Porcine Respiratory Coronavirus, all 
enveloped viruses as well, indicates that an non-specific damage of the virus 
envelope, caused by hydrophobic and electronegative interaction between the 3-
HP-proteins and the envelope proteins, is unlikely [102]. 
Previous studies confirmed that β-lactoglobulin and α-lactalbumin after 
modification with 3-Hydroxypthalic anhydride (3HP) [14, 78], human serum 
albumin, modified in strongly negative charged compounds [69] and lysozyme or 
modified lysozyme fragments [102] possess antiviral properties. 
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2.9 Chemical substances 
 
2.9.1 Ribavirin 
 
Ribavirin is a purine nucleotide analog that bears a close structural resemblance to 
guanosine. It has been often reported as an antiviral active substance against 
different viruses, like Respiratory Syncytial Virus, Hepatitis C Virus [75, 105] and 
BDV [72].  
Previous report demonstrated that Ribavirin possess antiviral activity against two 
different strains of BDV (strain V and He/80) present in two neural cell lines of 
different lineage (human oligodendrocytes and rat glia) [72]. 
Ribavirin is transported into cells and converted by cellular enzymes to mono-
phosphate derivates. It has been proved to be active against both RNA and DNA 
virus replication [104] and it shows a double mechanism of this inhibitory effect: 
firstly an inhibition of polymerase [93, 127]; secondly, an inhibition of transcription 
and capping of viral mRNA, due to a reduction of the intracellular GTP pool [42, 
72]. More in detail, the target reaction is the mRNA capping guanylation after 
phosporylation at the 5’ position [41, 51, 144]. 
There is evidence that both mechanisms are operative in BDV-infected cells treated 
with Ribavirin. The treated cells had lower levels of viral mRNAs, a result 
consistent with inhibition of transcription. Moreover, an even more striking effect 
was observed with respect to viral titers. This latter finding is in accord to an 
additional functional deficit in BDV transcripts due, as mentioned, to inhibition of 
capping and reduced efficiency of translation. Support for the hypothesis that 
Ribavirin acts through interference with GTP/dGTP biosyntesis has been found in 
other viral systems. Measles virus is an example where the antiviral effect of 
Ribavirin in vitro is abrogated by addition of guanosine but not adenosine [144].  
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2.9.2 Cytosine β-D-arabinofuranoside (CAF) 
 
CAF is a well known specific inhibitor of viral and cellular DNA polymerase [46]. 
It is a nucleoside analogue that differs from cytosine by the presence of a hydroxyl 
group at the 2’ position of the sugar residue. Its active metabolite, Ara-CTP, 
inhibits cellular and viral DNA polymerases [46]. Nevertheless, previous studies 
proved that it could also inhibit BDV, a negative-stranded RNA virus that 
synthesizes only RNA [7].  
The inhibitory effect of CAF on BDV replication and dissemination might be 
caused by direct effects on the viral replication machinery or by interference with 
host cell functions that the virus needs for its replication or spread. Even if CAF is 
known to have an antimitotic activity, that is the basis for its use in the treatment of 
leukemias. It has also been recently assessed that the antiviral effect of CAF against 
BDV cannot be attributed to its effect on the host cells at the concentration tested, 
because the BDV spread has resulted to be independent from the presence of 
antimitotic drugs [7]. So, it has been suggested that its effect is exerted directly on 
the viral replication machinery. In fact, CAF could directly inhibit the activity of 
the L- polymerase or alternatively it could exert a mutagenic effect during RNA 
synthesis mediated by BDV-L polymerase, resulting in the generation of high 
levels of non-functional viral genomes [7].  
Others authors recently reported CAF to have a strong activity also against BDV 
probably due to an inhibition of a RNA-dependent RNA polymerase as well [35, 
109, 141]. 
More in detail, CAF has been reported to exert not only a progressive inhibition of 
both genomic RNA and viral mRNA, but it influences as well the subcellular 
distribution of the viral proteins.  In fact, in untreated BDV-Vero cells, “N” and “P” 
viral proteins are localized both in the nucleus and in the cytoplasm [141]. With 
increasing concentration of CAF, both proteins disappeared from the cytoplasm and 
accumulated in the nucleus. Ribavirin treatment caused a comparable, but less 
drastic effect [7]. Since both “N” and “P” are basic constituents of viral 
ribonucleoparticles (RNP), their nuclear localisation is indicative of nuclear 
retention of viral RNP [7]. 
Taken together, all these data show that it is unlikely that CAF exerts its anti-BDV 
effect by interfering with the host cell machinery. However, the possibility cannot 
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be excluded that other unknown cellular pathways, important for the BVD 
replication, might be affected by CAF [7]. 
The activity of CAF has been reported also in vivo, where it has been described to 
inhibit BDV replication in the brain of infected rats, preventing persistent infection 
of the central nervous system as well as the development of clinical disease [7]. 
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2.9.3 Amantadine 
 
Amantadine sulfate is a well known substance which has been proved useful in the 
treatment and the prophylaxis of viral infections, in treating symptoms of 
Parkinson’s disease, cocaine dependence and apathy in multiple sclerosis [43].  
Besides these, a great number of other applications have been reported. For 
example, Amantadine is effective in post-herpetic neuralgia [48], in chronic fatigue 
syndrome of the multiple sclerosis patients [81], chronic hepatitis C [126], in the 
reduction of neuropathic pain [111] and in several others diseases [43]. 
Since 1966, it has been in use as an antiviral agent against influenza-A-virus 
infection. Its mechanism of action consists of an inhibition of the ion-channel 
activity of the M2 protein of the virus. It has been supposed that the drug acts by 
binding to a site in the open pore of the channel or altering its conformation through 
a distortion in one or more subunits [37, 107]. 
Amantadine was described as an antiviral active compound against BDV both in 
vitro and in vivo in a BDV-infected patient with bipolar depression [16]. 
Unfortunately, later studies couldn’t confirm its effectiveness [55] neither with 
respect to the number of infected cells nor in the levels of BDV RNA or proteins 
[28]. The importance of BDV infection for psychiatric disorders in general and for 
depressive disorders is currently a matter of debate [66, 68, 84, 96], and 
consequently a possible therapy with Amantadine has often been hypothesized. 
Divergent results have been reported as to whether Amantadine has any effect at all 
on BDV infection in vivo or in vitro [28, 55, 131]. Many authors, however, do not 
point to the fact that all data were obtained with a laboratory adapted animal virus 
strain, whereas others [16] used a human virus strain. In the latter case, some study 
clearly support an antiviral effect of Amantadine [43]. 
On the other hand, Amantadine fails to induce a clearance of BDV from BDV-
infected cells even if the results are not homogenous and susceptible for different 
interpretations: in fact, a recent study reports that no effect was detected on two cell 
lines (skin fibroblasts and astrocytic cell line F10 from Lewis rat and MDCK cells) 
while in one cell line (fibroblasts CRL 1405 from guinea pig), BDV virus was 
eliminated in one experiment with Amantadine at the concentration of 5 µg/ml 
[131]. Since the antiviral effect of Amantadine has so far not been reported to be 
dependent on the cell type used, the fibroblast CRL cell line might be 
extraordinarily sensitive to rather high concentrations of Amantadine. Alternatively 
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these results may indicate that Amantadine treatment of distinct cell lines yields a 
reduced intracellular virus titer without being able to eliminate the virus from those 
cells [84, 131]. 
In one of the newer studies, it has been reported as conclusion that permanent 
effects have never been ruled out entirely [43]. 
In vivo, Amantadine administered to rats had no influence on the time of onset of 
disease, neither on antiviral antibody titers, nor on virus titer in the brain, nor on the 
severity of neurological symptoms or encephalitic lesions [131]. 
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2.10 Objectives  
 
Considering the fact that no therapeutic approach has still been successively 
established against BD and the clinical significance of BDV infection has not been 
clarified, one aim of this study was to test different antiviral substances against BDV 
in persistently infected cells in vitro. Some of these compounds have already been 
reported as active against other viruses after chemical modification (β-lactoglobulin, 
albumin, lysozym, α-lactalbumin and bovine lactoferrin). Thus, it was interesting to 
test whether these compounds also possess antiviral activity against BDV. We were 
interested to study the antiviral activity of some substances whose antiviral properties 
against BDV were already described (Ribavirin and CAF), but their mechanisms were 
not yet assessed for sure. Another purpose of the study was to contribute to the 
controversial discussion about the antiviral activity of Amantadine. In order to 
appreciate a decrease of the infected cells attributable to an antiviral action, we tried 
to quantify the amount of infected cells when these substances were added to the 
culture medium during the incubation time. 
Moreover in order to investigate if the viral diffusion and multiplication was mainly 
due to a cell to cell spread or rather to a transmission of the virus through the division 
and replication of infected cells, we established a cell labelling method able to mark 
the cell lineage.  
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3. Materials and Methods 
 
 
3.1  Cell culture 
 
MDCK (Madin Darby canine kidney cells ATCC Nr. CCL-34), MDCK BDV-
infected cells (BDV isolate of the horse H1766) were a kind gift by Dr. S. Herzog, 
Institute of Virology, University of Giessen, Germany. 
Non infected Vero (Vero 76 African green monkey kidney cells) cells were 
disposable at the Institute of Veterinary pathology, Vetsuisse-Fakultät der Universität 
Zürich, Switzerland. 
Both cell lines (MDCK and Vero) were grown in Iscove’s Mod. Dulbecco’s Medium 
(Sigma®). To 500 ml medium, 50 ml 10% fetal bovine serum, inactivated at 60°C, 
12.5 ml Hepes buffer (Sigma®), 5 ml L-Glutamine (Sigma®, 200 mM) and 5 ml 
Penicillin-Streptomycin solution (Sigma®) were added. The cells were washed twice 
with PBS (Invitrogen®) and splitted using trypsin (Trypsin-EDTA Solution, 1X, 
Sigma®) every 3-4 days, diluted 1:40 and maintained at 37 °C with 5% CO2. Cells of 
both lines were trypsinized twice per week. 
Vero cells were infected using a persistently BDV MDCK infected monolayer.  
A confluent BDV persistently infected MDCK monolayer was split following the 
above described method. Then, the cell suspension was centrifuged at 800g for 10 
min. The supernatant was discarded, the cells washed twice with PBS, centrifuged 
again and stored. The probe was frozen at –20 C° for an hour, then melted in warm 
running water. The procedure was repeated four times. The obtained solution, clear 
with white flakes, was filtrated twice with a 0.8-0.2 µm filter, and then added to the 
Vero cells after splitting. 
Positive cells were first detected by indirect immunofluorescence after 2 weeks. Their 
number progressively increased for the next 3 weeks. After 4 weeks, ca. 98% of the 
cells were positive at the IIF. 
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3.2 Indirect Immunofluorescence (IIF) on cell cultures 
 
The indirect immunofluorescence studies were performed on cell monolayers 
obtained from cells incubated in Lab-Tek® Chamber™ Slide System  (from Nalge 
Nunc International) for three days (fig 1). 
 
 
a  b  
 
Fig.1, a: Lab-tek® Chamber™ Slide System. Cells are incubated with medium and tested compounds for three days. 
The total amount of cell solution in every well was 400 µl (containing 4 x 104 MDCK cells or 6 x 106  Vero cells); b: 
removal of the wells wall after the incubation. The slide was then analysed by immunofluorescence procedure. 
  
 
In each well of the Lab-tek®  (9x8 mm in size) 100 µl of a cell solution was dropped 
(4x105 /ml MDCK cells 6x 107/ml Vero cells). The volume in every well was brought 
to 400 µl by adding medium. Cells were incubated only with medium as negative 
control and with progressively higher concentrations of the substance to test, as 
reported in the scheme of figure 2. Every experiment was carried out in double, and 
each row of the Lab-Tek® wells (1 to 4 and 5 to 8) was considered an independent 
unit. 
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Addition of increasing concentrations of Ribavirin in medium. 
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Well 2 
1 µM Rib 
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Fig 2: layout of a Lab-tek® slide: placing of the negative control and progressive increasing concentrations of  
Ribavirin. 
 
 
After the incubation, medium was discarded, the plastic wells were removed and the 
monolayer was washed twice with PBS. The monolayers on the slide were fixed for 
20 min with –20°C Aceton at room temperature. 
Viral antigen was stained by adding 100 µl of 1:2000 diluted anti BDV-chicken 
serum (obtained from experimentally BDV infected chicken, gently gifted from Dr. S. 
Herzog, Institute of Virology, University of Giessen, Germany) in each well. The 
slide was then incubated for one hour at 37 °C and washed with PBS. 100 µl of 1:200 
diluted labelled antibody (Alexa Fluor® 488 goat anti-chicken IgG (H+L) were 
applied on every well and incubated again for one hour at 37 °C. They were washed 
with PBS and dipped 5 seconds in 1:10000 diluted Evan’s Blue as counter stain. The 
slides were extensively washed again with PBS, covered with cover glasses and the 
interposition of few drops of Glycerin (Kaisers Glyceringelatine, Merck) diluted 1:10 
with PBS. Finally the slides were analysed by fluorescence microscopy (Mikroskop 
LEICA DMLS) at a wavelength of 450-490 nm (filter I3 Leica).  
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3.3  Chemical modification of proteins 
 
The following proteins were chemically modified through reaction with 3-HP 
(Aldrich) as reported in the literature [102]: bovine serum albumin (BSA, Fluka®), 
lysozyme from chicken egg white (Fluka®), α-lactalbumin (Sigma), β-lactoglobulin 
(Sigma®) and bovine lactoferrin (gently gifted from Dr. Recio, Madrid). 
Briefly, 160 mg of the purified proteins were dissolved in 5 ml of 0.1 M Na-
phosphate buffer pH 8.5. 3-HP solution was added in eight aliquots of 200 µl (125 
mg/ml 3-HP dissolved in dimethylsulfoxyde) at 12 min. intervals. The solution was 
maintained at pH 8.5. After 1 hour incubation at 25 °C, the mixture was dialysed 
against 500 ml PBS pH 7.4 (Dialysation membranes Spectra/Por® MWCO: 6000-
8000). Protein concentration was determined photometrically as described [102]. 
Antiviral activity of Lactoferrin, β-lactoglobulin, albumin and lysozym had been 
tested both before and after chemical modification. 
α-lactoalbumin had been tested only after chemical modification. 
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3.4 Antiviral chemical compounds  
  
All the tested chemical compounds were purchased from Sigma®: 
Ribavirin (1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide), CAF (Cytosine β-D-
arabinofuranoside) and Amantadine (Amantadine hydrochloride). 
 
 
3.5 Tests on persistently BDV-infected cells 
 
A confluent BDV infected cells monolayer was split as reported in 3.1 and the cells 
suspension (ca. 2 x 106 cells/ml) of cells was diluted with medium (1:5 for MDCK 
and 1:3 for Vero cells). 
Then, 100 µl of cell solution was applied in every well of the Lab-Tek® and 300 µl 
medium were added. Then, the different concentrations of tested substances were 
added in every well, and the cells were incubated for three days at 37°C. The third 
day, the medium was discarded, and the Lab-tek® processed according to the IIF 
method described above. 
In order to standardise the number of infected cells and their variation, we considered 
5 fields on every well in predetermined placing: upper left, upper right, lower left, 
lower right and in the middle of the well. On each of these 5 fields, the number of 
positive cells (out of 100 cells) was counted. When the monolayer was somehow 
damaged or not homogenous, the predetermined placings were slightly rearranged, so 
that a cell count could be anyway performed.  
The obtained data were statistically processed by the Bonferroni’s multiple 
comparison test, using the application program ‘Prisma’. Results showing a P<0.05 
were considered statistically significant. 
 
 
3.6 Tests on BDV-infected and non infected cells 
 
Confluent monolayers of non infected and BDV persistently infected cells were split 
following the method described. The cell suspension (ca. 2 x 106 cells/ml) was diluted 
with medium (1:5 for MDCK cells, 1:3 for Vero cells). Then BDV-infected and non 
infected cells of the same cell line were mixed in a ratio of 1:400. After intensive 
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mixing, 100 µl of this solution were dropped in each well of the Lab-Tek® Chamber 
Slide™. Solution of different concentrations of substances or proteins to test were 
added in the incubation chambers and the final volume was brought to 400 µl with 
medium and incubated for three days at 37°C. 
One focus forming unit (FFU) was defined as the amount of virus required to form a 
cluster of several infected cells in the monolayer, identified by IF [55]. The number of 
fluorescent cell foci and the number of fluorescent cells per focus were reported. In 
the contest of the study, the expression FFU was used to indicate a cluster of BDV 
infected cells. 
Data obtained were statistically processed by the Bonferroni’s multiple comparison 
test, as described above. 
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3.7 Cell labelling by CMTPX 
 
In our investigation, both the number of FFU and the number of fluorescent cells per 
FFU were evaluated. In order to investigate if a reduction of the number of infected 
cells was due to a cytostatic or cytotoxic effect of the tested substances, or rather to 
an inhibition of the virus spread from cell to cell, we developed a procedure which 
uses the cell marker CMTPX (CellTracker Red CMTPX Molecular Probes). 
CMTPX, as another cells tracker widely documented (CFSA) to recognize viable cell 
progeny [6, 82, 88]. Moreover, and differently from other cell markers, CMTPX has 
the property not to interfere with the green Alexa fluorochrom staining. It is visible 
when excited at 613 nm. This property makes this compound very useful to 
investigate the viral spread. 
CMTPX is a cell tracker dye that is retained in living cells through several 
generations. It is inherited by daughter cells after cell fusion, equally apportioned 
between the two daughter cells and it is not transferred to adjacent cells in a 
population. When incubated with living cells, it passes freely through cell 
membranes, but once inside the cell, it is transformed into a cell-impermeant reaction 
product [1]. CMTPX contains a chloromethyl group that reacts with thiol groups 
present in proteins through a glutathione S-transferase-mediated reaction. In this way 
CMTPX is transformed into a cell-impermeant fluorescent dye – thioether adduct. 
Excess unconjugated reagent passively diffuses to the extracellular medium. The 
fluorescent signal, as in other cell markers like carboxyfluoroscein, progressively 
halves with each mitosis [45]. CMTPX yields a brightly red cytoplasmatic staining 
when examined by fluorescence microscopy (LEICA DMLS) at the wavelength of 
575 nm (filter G/R Leica). However, CMTPX doesn’t emit any appreciable light 
when excited in the range of 450-490 nm (Alexa fluorochrom excitation spectrum). 
The number and the size of every FFU were reported as previously described. In our 
study, we investigated the number of daughter cells per FFU (CMTPX labelled and 
BDV-infected cell), the number of new infected cells per FFU (CMTPX non 
labelled, BDV-infected cells) and the number of FFU constituted only by daughter 
cells . 
Data were statistically processed by the Bonferroni’s multiple comparison test, as 
described above. 
Cells were labelled with CMTPX as follows: 
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BDV infected cells were trypsinized and 980 µl of cells suspension were incubated 
with 20 µl CMTPX 1mM for one hour at 37 °C. Every 15 min the probe was gently 
stirred for about 15 sec. The probe was then centrifuged (5 min, 500 g), the 
supernatant discarded, replaced with the same volume of medium and incubated 30 
min at 37 °C. The cells were centrifuged once again, medium was discarded, and the 
cells washed twice with PBS. Finally, the same volume of medium was replaced in 
order to restore the original cell concentration. Cells were diluted with medium (1:5 
for MDCK and 1:3 for Vero) and then incubated for three days together with non 
infected cells (ratio 1:400). The compounds to be tested were added into the assay 
mixture as previously described. Cells were then investigated using a fluorescence 
microscope. Evan’s blue counter stain was not used because it produces interferences 
with CMTPX. 
At the concentration used, CMTPX did not produce any toxic effect on the cells: they 
were grown until confluence after three days incubation without any change in shape, 
morphology or density on optical control. 
When the cell monolayer was analysed at 450 nm (filter I3 Leica), only the infected 
cells were visible, organized in FFU. Using an excitation light of 613 nm (filter 
G/R), both fluorochrom Alexa (and then BDV infected cells) and CMTPX appeared 
lightened. 
 
3.8 Statistical analysis 
 
The data obtained were statistically processed through the Bonferroni’s multiple 
comparison test, using the application program ‘Prisma’. Results showing a P<0.05 
were considered significant. In the graphics reported, the box represents the 
interquartile range, the whiskers represent the maximum and the minimum value 
observed and the bold line represents the median. Additionally, tables are reported in 
the annex showing more in detail mean and standard deviation of every group of 
data. 
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4. Results 
 
4.1 Cell culture  
 
BDV non infected cells assessed with IIF appeared as uniform dark monolayer (fig. 
3). Only at the highest magnification (objective 40x) it was possible to distinguish 
the nucleus from the cytoplasm. 
BDV infected cells showed multiple, round, bright yellow inclusions in the nucleus 
(fig.4, a and b). The cytoplasm appeared dark, but the cell borders were almost quite 
easily visible. With the dilutions and the incubation time described, cells grew on the 
wells confluently. In a persistently BDV infected monolayer the percentage of cells 
positive was 85 to 100% for MDCK cells and 90 to 100% for Vero cells. 
When infected cells were incubated with non infected cells, IIF positive cells were 
grouped in clusters, indicated as focus forming unit (FFU) and surrounded by 
negative cells (fig.5 and 6). The number and the size of the FFU (expressed as the 
number of infected cells per FFU, see 3.6) were counted and statistically analysed. 
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a  b  
 
Fig. 3: MDCK non infected monolayer, 10x objective (a) and 40x objective (b), immunofluorescence microscope, filter I3 
Leica. 
 
 
a  b  
 
Fig. 4: MDCK BDV persistent infected monolayer, 20x objective (a), 40x objective (b) immunofluorescence microscope, filter 
I3 Leica. 
 
 
      
 
Fig. 5 and 6: MDCK BDV infected cells organized in FFU, 40x objective, immunofluorescence microscope, filter I3 Leica.  
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4.2 Antiviral activity of the native and modified proteins on BDV- 
 
infected MDCK cells 
 
The proteins lactoferrin, β-lactoglobulin, albumin, lysozyme were tested for antiviral 
activity both before and after chemical modification. 
3-HP was also tested as a negative control at the concentrations of 10, 20, 200 µM 
and 2, 20 mM. Since the cell monolayer appeared complete after the three days 
incubation and no morphological changes in density, shape and size were detected, 
the possibility of an intrinsic cytotoxicity was ruled out. 
All the proteins were tested on MDCK BDV persistently infected cells and on 
MDCK BDV infected and non infected cells incubated together. 
 
 
4.2.1 Bovine lactoferrin 
 
Native bovine lactoferrine was tested at the concentration of 3.0, 6.0 and 12.0 µM. 
Lactoferrin did not show any effect on cell growth and/or any cytotoxic effect like 
changes in cells morphology, size or shape, or density. Moreover, the cell monolayer 
appeared confluent and homogeneous after the standard incubation time. 
The percentage of infected cells showed a slight reduction when incubated with all 
the three concentrations of lactoferrin compared to the control (incubated only with 
medium), but without statistical significance (data not shown). The number and the 
size of FFU did not show any change. 
After chemical modification, 3-HP lactoferrine was tested at the concentration of 0.3, 
0.6, 1.25 µM and in all tests a marked inhibition of the cells growth was present, 
suggesting a strong cytotoxicity of this compound. 
 
 
4.2.2 β-Lactoglobulin 
 
β-Lactoglobulin was tested at the following concentrations: 3.0, 6.0, 12.0, 25, 50, 
100 µM. Neither the percent of infected cells nor the number or the size of the FFU 
showed any change. 
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3-HP β-lactoglobulin had an inhibitory effect on cell replication at concentrations 
higher than 1 µM. In this case, the monolayer obtained was not homogeneous, and 
the cell density was reduced. The count of the number of infected cells was not 
reliable. Anyway, no change in the percentage of infected cells or in the number and 
in size of the FFU was detectable. 
 
 
4.2.3 Albumin 
 
Albumin and 3-HP albumin were tested at the following concentration: 0.5, 1, 5 and 
10 µM. Both the substances exerted a strong cytotoxic effect on the cell growth.  
 
 
4.2.4 Lysozyme 
 
Lysozyme was tested at the following concentrations: 3.0, 6.0, 12.0, 25, 50, 100 µM 
It did not show any antiviral activity. 3-HP Lysozyme strongly inhibited the cell 
growth at all the concentrations of 1, 5, 10, 20, 50 µM. 
 
 
4.2.5 3-HP α-lactalbumin 
 
3-HP α-lactalbumin was tested at the following concentrations: 0.5, 1, 5, 10 µM. 
No significant reduction of the percent of BDV infected cells. When both infected 
and non infected cells were incubated with 3-HP α-lactalbumin, a slight inhibition on 
the cell growth at the concentration of 5 µM was noticed. This could suggest a higher 
selective sensitivity of the non infected cells compared to the BDV infected cells to 
the 3-HP α-lactalbumin. 
With concentrations lower than 5 µM, no reduction in the number or size of FFU was 
detectable. 
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4.3 Anti BDV activity of chemical antiviral substances  
  
4.3.1 Antiviral activity on BDV persistently infected cells: 
 
 4.3.1.1  Ribavirin 
 
The percentage of MDCK infected cells incubated with different concentrations of 
Ribavirin (1, 4, 8 µM) progressively decreased with increasing the concentrations of 
Ribavirin (fig.7a). Statistical significance was detected for 0 vs. 8 µM Ribavirin 
(P<0.01). 
Similar results were obtained with Vero cells (fig.8a): statistically significant 
reduction in the percentage of infected cells was detected for 0 vs. 8 µM Ribavirin 
(P<0.05).  
 
 4.3.1.2  CAF 
 
The percentage of MDCK infected cells decreased when incubated with CAF. In 
particular, the differences for 0 vs. 1 µM (P<0.05) and for 0 vs. 4 and 0 vs. 8 µM 
(P<0.01) of CAF were statistically significant (fig.7b) 
When persistently infected Vero cells were incubated with CAF (1, 2 or 4 µM), no 
statistically significant change in the percentage of infected cells could be noticed 
(fig.8b) 
  
 4.3.1.3 Amantadine 
 
Amantadine was tested at the following concentrations: 0, 16, 32, 64 µM. The 
decrease of the percentage of MDCK infected cells was statistically significant only 
between the 0 and 64 µM (P<0.01) (fig.7c). 
No statistically significant change has been detected in the same tests using Vero 
cells (fig.8c). 
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Fig. 7: (a) Effect of Ribavirin on BDV persistently infected MDCK cells. The percentage of BDV infected cells is 
reported as a function of the concentration of Ribavirin. Statistically significant difference was detected (P<0.01) for 
0 vs. 8 µM. (b) Effect of CAF on BDV persistently infected MDCK cells. The percentage of BDV infected cells is 
reported as a function of the concentration of CAF. Statistically significant difference was detected (P<0.05) for 0 
vs. 1 µM, P<0.01 for 0 vs. 4 and 0 vs. 8 µM. (c) Effect of Amantadine on BDV persistently infected MDCK cells. 
The percentage of BDV infected cells is reported as a function of the concentration of Amantadine. Statistically 
significant difference was detected (P<0.01) for 0 vs. 64 µM. 
In the graphics the box represents the interquartile range, the whiskers represent the maximum and the minimum 
value observed and the bold line represents the median.
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Fig. 8: (a) Effect of Ribavirin on BDV persistently infected Vero cells. The percentage of BDV infected cells is 
reported as a function of the concentration of Ribavirin. Statistically significant difference was detected (P<0.05) for 
0 vs. 8 µM. (b) Effect of CAF on BDV persistently infected Vero cells. The percentage of BDV infected cells is 
reported as a function of the concentration of CAF. No statistically significant difference was detected. 
(c) Effect of Amantadine on BDV persistently infected Vero cells. The percentage of BDV infected cells is reported 
as a function of the concentration of Amantadine. No statistically significant difference was detected. See fig. 7 for 
key. 
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4.3.2 Antiviral activity on size and number of Focus Forming Units (FFU)  
 
To investigate the anti BDV activity of some antiviral substances on BDV infected 
and non infected cells, the number of FFU and their size (that was expressed as the 
number of infected cells per FFU) was evaluated. 
  
4.3.2.1 Ribavirin 
 
Ribavirin concentrations tested on MDCK cells in the assays were 1, 4, 8 µM. At 
these concentrations of Ribavirin, the number of FFU remained unchanged, their size 
decreased significantly following a dose dependent course (fig.9 a and b). A 
statistically significant reduction in the size of the FFU was detectable (P<0.001) 
when the results obtained for the following concentration were compared for 0 vs. 4, 
0 vs. 8, 1 vs. 4 and 1 vs. 8 µM. 
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Fig. 9: Effect of Ribavirin on BDV infected and non infected MDCK cells. (a) The number of FFU is reported as a 
function of the concentration of Ribavirin. No statistically significant difference was detected. (b) The size of the 
FFU (expressed as the number of BDV infected cells per FFU) is reported as a function of the concentration of 
Ribavirin. Statistically significant difference was detected (P<0.001) for 0 vs. 4, 0 vs. 8, 1 vs. 4 and 1 vs. 8 µM. See 
fig. 7 for key. 
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The same concentrations of Ribavirin did not lead to any statistically significant change neither 
in the number nor in the size of FFU in Vero cell tests (fig.10 a and b). 
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Fig. 10: Effect of Ribavirin on BDV infected and non infected Vero cells. (a) The number of FFU is reported as a 
function of the concentration of Ribavirin. No statistically significant difference was detected. (b) The size of the 
FFU (expressed as the number of BDV infected cells per FFU) is reported as a function of the concentration of 
Ribavirin. No statistically significant difference was detected. See fig. 7 for key. 
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4.3.2.2 CAF 
 
On MDCK cells, CAF was tested at concentrations of 1, 4, 8 µM. The decreased 
number of FFU is statistically significant (P<0.01) for concentration of 0 vs. 4 and 0 
vs. 8 µM. 
At the same time also the size of the FFU decreased following a dose dependent 
course. The size of FFU differed highly statistically significant (P<0.001) for the 
following concentrations: 0 vs. 1, 0 vs. 4, 0 vs. 8, 1 vs. 4 and 1 vs. 8) (fig. 11 a and 
b). 
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Fig. 11: Effect of CAF on BDV infected and non infected MDCK cells. (a) The number of FFU is reported as a 
function of the concentration of CAF. Statistically significant difference was detected (P<0.01) for 0 vs. 4 and 
0 vs. 8 µM. (b) The size of the FFU (expressed as the number of BDV infected cells per FFU) is reported as a 
function of the concentration of CAF. Statistically significant difference was detected (P<0.001) for 0 vs. 1, 0 
vs. 4, 0 vs. 8, 1 vs. 4 and 1 vs. 8 µM. See fig. 7 for key. 
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On Vero cells, CAF was tested at concentrations of 1, 2, 4 µM. For higher concentrations, 
cells density appeared reduced and the monolayer did not grow on all the available surface 
of the well. The number of FFU was highly significantly decreased (P<0.001), in presence 
of CAF, for concentrations of 0 vs.1, 0 vs. 2 and 0 vs. 4 µM. 
Similar results were obtained considering the size of the FFU (P<0.001) for 
concentrations of CAF 0 vs.1, 0 vs. 2 and 0 vs. 4 µM (fig.12 a and b). No statistically 
significant differences between the tested concentrations of CAF regarding the 
number and the size of the FFU were noted 
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Fig. 12: Effect of CAF on BDV infected and non infected Vero cells. (a) The number of FFU is reported as a 
function of the concentration of CAF. Statistically significant difference was detected (P<0.001) for 0 vs. 1, 0 
vs. 2 and 0 vs. 4 µM. (b) The size of the FFU (expressed as the number of BDV infected cells per FFU) is 
reported as a function of the concentration of CAF. Statistically significant difference was detected (P<0.001) 
for 0 vs. 1, 0 vs. 2 and 0 vs. 4 µM. See fig. 7 for key. 
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4.3.2.3 Amantadine 
  
No difference was detected neither in the number of FFU nor in their size at 
concentrations of 16, 32, 64 µM of Amantadine when compared with the negative 
control on both MDCK and Vero the cell lines (fig.13 a and b and 14 a and b). 
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Fig. 13: Effect of Amanatdine on BDV infected and non infected MDCK cells. (a) The number of FFU is 
reported as a function of the concentration of Amantadine. No statistically significant difference was detected. 
(b) The size of the FFU (expressed as the number of BDV infected cells per FFU) is reported as a function of 
the concentration of Amantadine. No statistically significant difference was detected. See fig. 7 for key. 
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Fig. 14: Effect of Amanatdine on BDV infected and non infected Vero cells. (a) The number of FFU is reported 
as a function of the concentration of Amantadine. No statistically significant difference was detected. (b) The 
size of the FFU (expressed as the number of BDV infected cells per FFU) is reported as a function of the 
concentration of Amantadine. No statistically significant difference was detected. See fig. 7 for key. 
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4.4 Progression of infection, use of CMTPX as cell marker. 
 
Tests using CMTPX as cell marker were performed on both cell lines. As described 
in 3.7, BDV infected and CMTPX labelled cells were incubated with BDV non 
infected cells.  
With the use of CMTPX as cell label and reading the slides using a fluorescence 
microscope, filter G/R Leica, both stainings were clearly visible: Alexa 
immunofluorescence as bright yellow nuclear inclusions and CMTPX label as red, 
diffuse cytoplasmatic staining (fig.15 a and b). In the following discussion, the 
definition of ‘CMTPX positive’ cell indicates a cell labelled with CMTPX, that was 
a daughter cell coming from the original BDV persistently infected monolayer.  
Therefore, there were four possible cell conditions:  
• double negative cell; 
• CMTPX positive and BDV-negative cell (indicated as CMTPX positive); 
• CMTPX negative and BDV-positive (indicated only as infected cell); 
• double positive cell (BDV positive and CMTPX positive). 
The composition of every FFU was investigated and reported. In detail, there were 
three possible types of FFU were observed: 
• FFU where all the cells were double positive (it means that all the infected 
cells were coming from the same original CMTPX incubated cells) (fig.16 a 
and b); 
• FFU where the infected cells (but CMTPX negative) cells were more 
numerous than the CMTPX positive cells (fig.17 a and b). These represent 
the cells that have been infected during incubation by the virus spread from 
cell to cell or from free virus in the medium; 
• FFU where the CMTPX positive (but non infected) cells were more 
numerous than the infected cells (fig.18 a and b). In this case, the virus has 
not been successfully transmitted through the cell replication or the cells 
come from negative cells present in the persistently infected monolayer. 
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 a   b  
 
Fig. 15 a : In a MDCK BDV negative monolayer, some cells were incubated with CMTPX (in a ratio of 1:400). With the filter 
I3 Leica (a), CMTPX staining was not visible. With the filter G/R Leica (b), CMTPX labelled cells are clearly visible. 40x 
objective. 
 
 
a  b  
 
Fig. 16 a and b: BDV infected Vero cells organized in FFU, positive at indirect immunofluorescence. Alexa staining is visible 
using the filter I3 Leica (a) as well as using the filter G/R Leica (b). CMTPX staining is only visible using the filter G/R Leica. 
In this case all the cells composing the FFU are daughter cells from the original BDV infected monolayer CMTPX labelled. 
40x objective. 
 
 
a  b  
 
Fig. 17 a and b: BDV infected MDCK cells organized in FFU, positive at the indirect immunofluorescence. Fluorochrom Alexa 
staining is visible using the filter I3 Leica (a) as well as using the filter G/R Leica (b). CMTPX staining is only visible on the 
filter G/R Leica. In this case, only two of the BDV positive cells composing the FFU come from the cell linage labelled with 
CMTPX. BDV positive cells but not CMTPX labelled are interpreted as infected probably due to virus spread from cell to cell. 
40x objective. 
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a  b  
 
Fig. 18 a and b: BDV infected MDCK cells organized in FFU, positive at the indirect immunofluorescence. Fluorochrom Alexa 
staining is visible using the filter I3 Leica (a) as well as using the filter G/R Leica (b). CMTPX staining is only visible on the 
filter G/R Leica (b). In this case, the CMTPX labelled cells are more numerous than the BDV infected cells. These are 
interpreted as cells coming from the original BDV persistently infected monolayer that didn’t transmit the infection through the 
cell multiplication. 40xobjective. 
 
 
 
In order to show the composition of every single FFU, the proportion of the daughter 
cells in every FFU was related to the number of infected cells. It was expressed as 
the number of double positive cells divided by the number of BDV infected cells in 
the correspondent FFU. 
In the same way, the number of newly infected cells in every FFU was reported as 
the number of BDV infected but CMTPX-negative cells divided by the total number 
of BDV infected cells in the correspondent FFU. 
Moreover, the proportion of FFU composed of only double positive cells was 
reported, calculated as the ratio between the number of FFU composed of only 
double positive cells divided by the total number of FFU in the well. 
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4.4.1 Ribavirin 
 
On MDCK cells the same concentrations of Ribavirin of the previous experiments 
(see 4.3.2.1) were tested (1, 4, 8 µM) and no reduction in the number of FFU was 
assessed (fig. 19a). 
The number of FFU only composed of double positive cells showed a constant 
increase, statistically significant at the concentration of 8 µM (P<0.05), compared to 
the negative control (fig.19b). 
A reduction in the size of the FFU was detected, statistically significant: P<0.01 for 0 
vs. 4, P<0.05 for 1 vs. 4 µM. P<0.001 for 0 vs. 8 and 1 vs. 8 µM (fig.19c). 
The number of new infected cells per FFU significantly and progressively decreased 
with the addition of Ribavirin. P<0.05 for 0 vs. 8 µM and 1 vs. 4 µM. P<0.01 for 1 
vs. 8 µM (fig.19d). 
The number of daughter cells per FFU was not dependent on the Ribavirin 
concentration present in the assay (fig.19e). 
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Fig. 19: Effect of Ribavirin on BDV infected and non infected MDCK cells. (a) The number of FFU is reported 
as a function of the concentration of Ribavirin. No statistically significant difference was detected. (b) The 
number of FFU without new infected cells is reported as a function of the concentration of Ribavirin. 
Statistically significant difference was detected (P<0.05) for 0 vs. 8 µM. (c) The size of the FFU (expressed as 
the number of BDV infected cells per FFU) is reported as a function of the concentration of Ribavirin. 
Statistically significant difference was detected (P<0.01) for 0 vs. 4; P< 0.001 for 0 vs. 8 and 1 vs. 8; P<0.05 
for 1 vs. 4 µM. (d) The number of new infected cells per FFU is reported as a function of the concentration of 
Ribavirin. Statistically significant difference was detected (P<0.05) for 0 vs. 8, 1 vs. 4; P<0.01 for 1 vs. 8 µM. 
(e) The number of daughter cells per FFU is reported as a function of the concentration of Ribavirin. No 
statistically significant difference was detected.See fig. 7 for key. 
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When Ribavirin was tested on BDV infected and non infected Vero cells, the number and 
the size of the FFU as well as the number of daughter cells per FFU remained unchanged 
(fig. 20 a, b, c, e) 
The only statistically significant difference was observed in the decreased number of 
new infected cells per FFU (P<0.05) for 0 vs. 1 µM (fig. 20 d). 
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Fig. 20: Effect of Ribavirin on BDV infected and non infected Vero cells. (a) The number of FFU is reported 
as a function of the concentration of Ribavirin. No statistically significant difference was detected. (b) The 
number of FFU without new infected cells is reported as a function of the concentration of Ribavirin. No 
statistically significant difference was detected. (c) The size of the FFU (expressed as the number of BDV 
infected cells per FFU) is reported as a function of the concentration of Ribavirin. No statistically significant 
difference was detected. (d) The number of new infected cells per FFU is reported as a function of the 
concentration of Ribavirin. Statistical significant difference was detected (P<0.05) for 0 vs. 1 µM. (e) The 
number of daughter cells per FFU is reported as a function of the concentration of Ribavirin. No statistically 
significant difference was detected.See fig. 7 for key. 
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4.4.2 CAF 
 
CAF was tested on BDV infected and non infected MDCK cells at the concentrations 
of 1, 2, 4 µM. 
The number of FFU showed a statistically significant decrease (P<0.01 for 0 vs. 4 
µM) (fig. 21 a).  
The number of FFU composed only of daughter cells showed a progressive, 
significant enhance: P<0.01 for negative control vs. 1 and vs. 2 µM; P<0.001 in 0 vs. 
4 and 1 vs. 4 µM (fig. 21b). 
Also the size of the FFU decreased with statistical relevance: P<0.01 for 1 vs. 2 µM, 
P<0.001 for 0 vs. 1, 0 vs. 2, 0 vs. 4 and 1 vs. 4 µM of CAF (fig.21 c). 
The number of daughter cells significantly decreased in presence of 1 µM of CAF in 
assay (P<0.05). The number of new infected cells was as well strongly reduced by a 
CAF concentration of 4 µM (P<0.001 0 vs. 1, 0 vs. 2 and 0 vs. 4 µM) (fig.21, d and 
e). 
 53
 (a)
0 1 2 4
0
10
20
30
40
CAF (µM)
N
o 
FF
U
(b)
0 1 2 4
0.55
0.60
0.65
0.70
0.75
0.80
0.85
0.90
0.95
1.00
1.05
CAF (µM)
FF
U
 w
ith
ou
t n
ew
 in
fe
ct
ed
 c
el
ls
(c)
0 1 2 4
50
150
CAF (µM)
Si
ze
 o
f F
FU
(d)
0 1 2 4
0.00
0.25
0.50
0.75
1.00
1.25
CAF (µM)
N
ew
 in
fe
ct
ed
 c
el
ls
 p
er
 F
FU
(e)
0 1 2 4
0.0
2.5
5.0
7.5
10.0
12.5
CAF (µM)
D
au
gh
te
r 
ce
lls
 p
er
 F
FU
 
 
 
Fig. 21: Effect of CAF on BDV infected and non infected MDCK cells. (a) The number of FFU is reported as 
a function of the concentration of CAF. Statistically significant difference was detected (P<0.01) for 0 vs. 4 
µM (b) The number of FFU without new infected cells is reported as a function of the concentration of CAF. 
A statistically significant difference (P<0.01) was detected for 0 vs. 1 and 0 vs. 2; P< 0.001 for 0 vs. 4 and 1 
vs. 4 µM. (c) The size of the FFU (expressed as the number of BDV infected cells per FFU) is reported as a 
function of the concentration of CAF. A statistically significant difference was detected (P<0.001) for 0 vs. 1, 
0 vs. 2, 0 vs. 4, 1 vs 4; P<0.01 for 1 vs. 2 µM. (d) The number of new infected cells per FFU is reported as a 
function of the concentration of CAF. Statistically significant difference was detected (P<0.001) for 0 vs. 1, 0 
vs. 2 and 0 vs. 4  µM. (e) The number of daughter cells per FFU is reported as a function of the concentration 
of CAF. A statistically significant difference was detected (P< 0.05) for 0 vs. 1 µM. See fig. 7 for key. 
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CAF was tested on BDV infected and non infected Vero cells at the concentrations 
of 1, 2, 4 µM. A decreased number of FFU, statistically significant (P<0.05) was 
detected at the concentration of of 0 vs. 1, 0 vs. 2, 0 vs. 4 µM (fig.22 a).  
The number of FFU composed exclusively of daughter cells decreased with a 
statistically significant difference (P<0.001) for 0 vs. 1, 0 vs. 2 and 0 vs. 4 µM 
(fig.22 b). 
Also the size of the FFU decreased statistically significant (P<0.001) for 
concentration of CAF of  0 vs. 1, 0 vs. 2, 0 vs. 4 (fig.22 c). 
The same significant decrease has been observed in the number of daughter cells per 
FFU (P<0.001) for 0 vs. 1, 0 vs. 2 and 0 vs. 4 µM and in the number of new infected 
cells per FFU (P<0.001) for 0 vs. 1, 0 vs. 2 and 0 vs. 4 µM (fig.22 d and e). No dose 
dependent differences between the tested concentrations of CAF was noted. 
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Fig. 22: Effect of CAF on BDV infected and non infected Vero cells. (a) The number of FFU is reported as a 
function of the concentration of CAF. Statistically significant difference was detected (P<0.05) for 0 vs. 1, 0 
vs. 2 and 0 vs. 4 µM. (b) The number of FFU without new infected cells is reported as a function of the 
concentration of CAF. A statistically significant difference (P<0.001) was detected for 0 vs. 1, 0 vs. 2 and 0 
vs. 4 µM. (c) The size of the FFU (expressed as the number of BDV infected cells per FFU) is reported as a 
function of the concentration of CAF. Statistically significant difference was detected (P<0.001) for 0 vs. 1, 0 
vs. 2, 0 vs. 4 µM. (d) The number of new infected cells per FFU is reported as a function of the concentration 
of CAF. A statistically significant difference was detected (P<0.001) for 0 vs. 1, 0 vs. 2 and 0 vs. 4 µM. (e) 
The number of daughter cells per FFU is reported as a function of the concentration of CAF. A statistically 
significant difference was detected (P < 0.001) for 0 vs. 1, 0 vs. 2 and 0 vs. 4 µM. See fig. 7 for key. 
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4.4.3 Amantadine 
 
Amantadine was tested on BDV infected and non infected MDCK cells at the 
following concentrations: 0, 16, 32, 64 µM. None of the considered parameters 
showed any variations when MDCK cells were incubated with Amantadine (fig.23, a 
- e). 
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Fig. 23: Effect of Amantadine on BDV infected and non infected MDCK cells. (a) The number of FFU is 
reported as a function of the concentration of Amanatadine. No statistically significant difference was 
detected. (b) The number of FFU without new infected cells is reported as a function of the concentration of 
Amantadine. No statistically significant difference was detected. (c) The size of the FFU (expressed as the 
number of BDV infected cells per FFU) is reported as a function of the concentration of Amantadine. No 
statistically significant difference was detected. (d) The number of new infected cells per FFU is reported as a 
function of the concentration of Amantadine. No statistically significant difference was detected. (e) The 
number of daughter cells per FFU is reported in function of the concentration of Amantadine. No statistically 
significant difference was detected. See fig. 7 for key. 
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Amantadine was tested on BDV infected and non infected Vero cells at the following 
concentrations: 0, 16, 32, 64 µM. 
The number of FFU remained unchanged (fig.24 a) as the number of FFU composed 
exclusively of daughter cells with the addition of Amantadine (fig. 24 b). 
A decrease in the size of the FFU has been detected at the following concentrations: 
P<0.01 for 0 vs. 16 and P<0.001 for 0 vs. 64 µM (fig.24 c). 
The number of daughter cells per FFU did not showed any change, while the number 
of new infected cells is significantly decreased: P< 0.05 for 0 vs. 16 and 0 vs. 64 µM, 
and P<0.01 for 0 vs. 32 µM (fig.24 d and e). 
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Fig. 24: Effect of Amantadine on BDV infected and non infected Vero cells. (a) The number of FFU is 
reported as a function of the concentration of Amanatadine. No statistically significant difference was 
detected. (b) The number of FFU without new infected cells is reported as a function of the concentration of 
Amantadine. No statistically significant difference was detected. (c) The size of the FFU (expressed as the 
number of BDV infected cells per FFU) is reported as a function of the concentration of  Amantadine. 
Statistically significant difference was detected for 0 vs.16; P<0.001 for 0 vs. 64 µM. (d) The number of new 
infected cells per FFU is reported as a function of the concentration of Amantadine. A statistically significant 
difference was detected (P<0.05) for 0 vs. 16 and 0 vs. 64; P<0.01 for 0 vs. 32 µM. (e) The number of 
daughter cells per FFU is reported as a function of the concentration of Amantadine. No statistically 
significant difference was detected. See fig. 7 for key. 
 
 60
5. Discussion 
 
 
5.1 Antiviral activity of proteins  
 
In this study both the native and modified albumin strongly impaired the cell 
growth. Chemically modified Lactoferrin, β-lactoglobulin and lysozyme proteins 
did also inhibit or markedly impair the cellular replication to such an extend that no 
cellular monolayer was obtained after three days of incubation, thus making an 
evaluation of a potential antiviral activity very difficult or even  impossible. 
 
In previous studies, the proteins which we tested had shown a marked antiviral 
activity against Human Herpes Simplex Virus type 1 [102], HIV and Human 
Cytomegalovirus [56], Adenovirus [4] and other viruses (see 4.2). 
Chemical modification through reaction with 3-HP of these proteins yields 
compounds which strongly inhibited the multiplication of Herpes Simplex Virus-1.  
However, since 3-HP-modified proteins failed to inhibit Bovine Parainfluenza 
Virus type 3 and Porcine Respiratory Coronavirus (all enveloped viruses as BDV) 
this indicates that an inhibition by unspecific damage of the virus envelope, caused 
by hydrophobic and electronegative interaction between the 3-HP-proteins and the 
envelope proteins, is unlikely. The native proteins and the chemical compound 3-
HP alone did not show any antiviral activity against the virus investigated, 
indicating that the inhibition of the cytopathic effect of HSV-1 was a peculiar 
property of the modified proteins [103]. 
 
 
5.2 Ribavirin 
 
Our investigations confirmed the antiviral activity against BDV of Ribavirin. 
Ribavirin proved to be active against BDV in persistently infected cells on both 
MDCK and Vero cells. 
The size of the FFU (expressed as the number of BDV infected cells per FFU) was 
reduced only on MDCK cells. This can be interpreted as a different sensitivity to 
Ribavirin depending on the cell line. It was interesting to investigate if the antiviral 
effect was a consequence of a reduction in the cell replication and consequently of 
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the viral transmission or due to an inhibition of the virus spread from cell to cell 
independent from the cell cycle. 
In order to assess, whether the infection was carried out mainly through inheritance 
of the virus in the cells progeny or through the passage of the virus from BDV 
infected to non infected cells, the cells were labelled with CMTPX and every single 
FFU was examined.  
Our result showed that the FFU were composed mainly of daughter cells that 
transmit the infection through their replication, confirming that the infectivity of the 
BDV for new cells is very low. 
Nevertheless, the proportion of infected cells that did not derive from the original 
persistent infected monolayer could be quantified, showing that in this case the size 
reduction of the FFU was attributable to a parallel reduced number of new infected 
cells. As a consequence, the number of FFU without newly infected cells was 
slightly increased. 
Interestingly, the number of newly infected cells per FFU was the only parameter 
that statistically significantly decreased also in tests with Vero cells, but evidently 
not enough to determine a total variation of the progress of the infection. 
It appears therefore likely that the antiviral effect of Ribavirin can be attributed to a 
reduction of the virus spread from cell to cell and that this is partially dependent on 
the cell line used. 
 
 
5.3 CAF 
 
In this study, the strong antiviral anti-BDV activity of CAF previously reported [7, 
141] (see 2.9.2) could be confirmed.  
After incubation of CAF with persistently infected cells, only MDCK cells, but not 
Vero cells, showed a significant reduction of the percentage of infected cells, 
suggesting that also in this case the sensitivity to CAF treatment is dependent on 
the cell line. 
On other hand, both the number and the size of the FFU were significantly 
decreased in the presence of CAF during the incubation on both MDCK and Vero 
cell lines.  
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On both cell lines the FFU showed a tendency to be composed exclusively of 
daughter cells when incubated with CAF. This observation suggests that the virus 
spread form cells to cell can be limited or impaired by the presence of CAF. 
Additionally, both the number of new infected cells and the number of daughter 
cells per FFU were reduced showing that CAF probably can have an effect on the 
virus spread as well as on the multiplication of the infected cells. Considering 
however that the monolayer is completed after the standard incubation time, it can 
be excluded that the cytostatic effect of CAF would significantly  interefere with 
the cells growth. 
 
 
5.4 Amantadine 
 
In this study, we could find a statistically significant antiviral effect of Amantadine 
at the concentration of 64 µM only on BDV persistently infected MDCK cells. The 
same concentrations tested on Vero cells did not show any effect.  
On the other hand, incubation with Amantadine caused a reduction in the number 
of new infected cells per FFU and a reduced average size of the FFU on Vero cells, 
but the same concentration failed to show any effect on MDCK cells. 
These results firstly support the idea that different cell lines could have a different 
sensitivity to Amantadine, as previously presumed [16, 43](see 2.9.3).  
Moreover, the statistically significant reduction of the infected cells per FFU was 
detectable only in the experiment performed with the CMTPX, and not in the 
assays where BDV infected cells were not labelled.  
This suggests that CMTPX and Amantadine could have a synergic effect on Vero 
cells. However, this effect was not noticed on MDCK cells and needs to be further 
investigated.  
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5.5 Concluding remarks 
 
The main results of our study can be summarized as follows: 
• Confirmed antiviral effect of Ribavirin on BDV persistently infected MDCK cells 
and on the size of the FFU. This activity could be demonstrated to be  exerted 
through an impairment of the virus spread from cell to cell; 
• Antiviral effect of Ribavirin on BDV persistently infected Vero cells 
• Confirmed anti-BDV effect of CAF on BDV persistently infected MDCK cells and 
on the number and size of FFU on both MDCK and Vero cell lines. This antiviral 
activity has been demonstrated to be exerted through an impairment of the virus 
spread from cell to cell as well as on an inhibition of the replication of infected 
cells, on both the cell lines; 
• Antiviral effect of Amantadine on BDV persistently infected MDCK cells, but not 
on persistently infected Vero cells  
• Antiviral effect of Amantadine on the size of FFU on Vero cells, due to a reduction 
of the virus spread from cell to cell. This effect was not observed on MDCK cells 
 
Given the assumption that the cells growth is a biological, dynamic process and 
therefore hardly ever constant, even if the cultivation procedure is in itself 
standardized, every cell monolayer is somehow unique and different from all the 
others. The ideal cell monolayer is composed by definition of a single, uniform 
layer of cell that allows a good identification of the cells border and morphology. 
The numerical evaluation of the cell culture slides was limited by various factors: 
On each well of the slides there are inhomogenous areas, where the cell density is 
higher or lower, or where a certain degree of background reaction was present, a 
fact that made the counting procedure sometimes difficult. 
Moreover, the multiple fluorescent granules characterizing the BDV infected cells 
are typically present in the nucleus. Nevertheless, because of the partial overlapping 
of the cells, sometimes the exact number of positive cells was difficult to assess.  
Data issued from optical cell counts are generally prone to a certain degree of 
subjectivity, however this was sensibly reduced through the fact that the same 
person carried out all the experiments in a relatively short period of time. 
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CMTPX proved to be a useful marker to discriminate vertical and horizontal 
transmission of the virus in cell culture. A proportion of cells was labelled with 
CMTPX but did not appear BDV infected by immunofluorescence.  
In fact, these cells could be either part of the original BDV persistently infected cell 
line, that did not contain the virus (in a BDV persistently infected monolayer the 
majority, but not all of the cells are positive at immunofluorescence), or that they 
had lost the virus during the replication process. 
 
Another difficulty of this study was to establish a threshold of cytotoxicity when 
the cells were incubated with the compounds tested. As a rule, we excluded in the 
study those slides in which the monolayers showed diffuse changes in the cell 
morphology (shape and size) or in the cell density compared to the negative 
control. Optical control does not exclude variations in the kinetics of the cell 
growth. Confluence of the monolayers was always complete after 3 days of 
incubation, but might be reached earlier in non treated than in treated samples. 
Considering the fact that BDV requires a tight contact between the cells for a 
successful spread and that the infectivity of the virus is quite low [30], the question 
remains, if a delayed contact, due for example to a retardation of the cell growth, 
could affect the virus spread resulting in a impaired transmission of the infection 
from cell to cell. 
 
In spite of these limitations, this study clearly demonstrated an inhibition of virus 
growth and spread in cell culture by various antiviral compounds, such as 
Ribavirin, CAF and Amantadine, as well as a differential sensitivity of the two cell 
lines used. 
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7. Abbreviations 
 
 
1B6TM  1-0-benzyl-6-0-trityl-α-D-mannopyranoside  
3-HP  3-Hydroxypthalic anhydride 
BD   Borna Disease 
BDV   Borna Disease Virus 
CAF  Cytosine β-D-arabinofuranoside 
CFSA  5 (and 6) carboxyfluoroscein diacetate, succinimidyl ester 
CNS   Central Nervous System 
CSA   Cyclosporine A 
CSF  Cerebrospinal fluid 
CSFF  Cerebrospinal fluid filtration 
FFU   Focus Forming Unit 
HIV  Human Immunodeficiency Virus 
HSV  Herpes Simplex Virus  
IFN  Interferon 
IIF  Indirect Immunofluorescence  
MDCK  Madin Darby Canine Kidney cells 
NNS RNA Negative non-segmented Ribonucleic acid 
PBS   Phosphate Buffer Solution 
PO   phosphodiester oligonucleotide  
RNP  viral ribonucleoparticles 
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10. Annex 
 
Table 1. Percentage of BDV infected cells per field incubated with different concentrations of 
Ribavirin, CAF and Amantadine  
 
MDCK cells Vero cells   
 
µM Percentage of infected cells per field 
Statistical 
significance 
Percentage of infected 
cells per field 
Statistical 
significance 
0 94.30±6.20 95.00±8.87 
1 89.10±5.74 91.70±4.64 
4 81.00±10.98 88.50±7.00 
 
 
 
Ribavirin 
8 74.00±10.51 
 
 
 
P<0.01 for 0 vs. 8 
 
83.60±12.91 
 
 
 
P<0.05 for 0 vs 8 
 
0 94.30±6.20 98.60±1.90 
1 81.70±13.78 97.90±2.47 
4 77.90±9.36 98.10±0.88 
 
 
 
CAF 
8 72.30±5.80 
 
P<0.05 for 0 vs. 1 
 
P<0.01 for 0 vs. 4 
                  0 vs. 8 
 
97.70±2.36 
 
 
 
- 
 
0 97.00±2.12 94.90±4.18 
16 87.40±7.50 89.80±8.44 
32 88.40±4.61 88.60±5.38 
 
 
 
Amantadine 
64 88.90±9.93 
 
 
P<0.01 for 0 vs. 64 
 
 
90.90±8.28 
 
 
 
- 
 
 
Table 1: The reported data are mean, standard deviation and statistical significance (data are processed using the 
statistical application program ‘Prisma’, in particular through the Bonferroni’s multiple comparison test). Results 
with a P<0.05 were assumed to be significant. The different statistical significances as well, are reported. 
     Table 2. Number and size* of FFU when MDCK and Vero cells are incubated with different concentrations of Ribavirin, CAF and Amantadine.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MDCK cells Vero cells  
 
 
                      µM
 
No FFU 
Statistical 
significance 
 
Size* FFU 
Statistical 
significance 
 
No FFU 
Statistical 
significance 
 
Size* FFU 
 
Statistical 
significance 
0     37.00±16.79 27.78±20.97 29.00±2.94 6.91±5.54
1      37.00±12.03 26.32
(0.00, 52.92) 
23.25±7.27 5.70±4.70
4   34.00±18.74 14.84±10.76 26.00±3.92 5.34±4.29 
 
 
 
Ribavirin 
8  17.50±9.61
 
 
 
- 
9.71±8.57 
P<0.001 
 
for 0 vs. 4, 
      0 vs. 8, 
      1 vs. 4, 
      1 vs. 8 
 22.50±2.38 
 
 
 
- 
5.24±3.79 
 
 
 
 
- 
0   43.25±11.15 28.37±21.81 20.50±2.89 6.11±5.56 
1   28.75±9.91 17.98±16.80 5.75±4.11 1.09±0.29 
2   4.25±3.20 1.29±0.69 
4     13.25±10.18 4.81±3.26 4.75±1.26 1.00±0.00
 
 
 
CAF 
8  9.50±5.97
  
P<0.01  
 
for 0 vs. 4 
     0 vs. 8 
 
2.56±1.61 
 
P<0.001  
for 0 vs. 1,  
      0 vs. 4, 
      0 vs. 8,  
      1 vs. 4, 
      1 vs. 8 
 
  
 
P< 0.001  
for  0 vs. 1,  
      0 vs. 2,  
      0 vs. 4 
 
 
  
 
P< 0.001 
for  0 vs. 1,  
      0 vs. 2, 
      0 vs. 4 
 
0    48.93±11.98 23.37±18.97 56.25±10.84 6.36
(0.00,12.77) 
16   44.44±17.36 23.38±19.74 51.75±1.70 7.55
(0.00,15.35) 
32   35.00±18.06 27.05±22.81 60.00±10.03 6.36
(0.00,12.97) 
 
 
 
 
Amantadine 
64  50.38±14.70
 
 
 
 
- 
 
     
19.15±17.40 
 
 
 
 
- 
 
 
 
53.75±7.14 
 
 
 
 
- 
 
 
  6.49±5.74 
 
 
 
 
- 
 
 
 
Table 2: Data are reported as mean and standard deviation. Data are processed using the statistical application program ‘Prisma’, in particular through the Bonferroni’s multiple 
comparison test. Results with a P<0.05 were assumed to be significant. The different statistical significances as well, are reported. 
*: size of FFU is expressed as the number of BDV infected cells per FFU. 
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Table 3. Total number of FFU, number of FFU without new infected cells, size* of the FFU, number of new infected cells per FFU and number of  
daughter cells per FFU when MDCK cells are incubated with the different concentrations of  Ribavirin, CAF and Amantadine. 
 
MDCK   
 
µM No of FFU  Statistical Significance 
No of FFU 
without new 
infected cells 
Statistical 
Significance Size* of FFU 
Statistical 
Significance 
New infected 
cells per FFU 
Statistical 
Significance 
Daughter 
cells per FFU 
Statistical 
Significance 
0  23.23±13.69 0.66±0.17 27.79±21.34 
0.07 
(0.00, 0.26) 
 
1.05 (0.00, 
2.16) 
1 21.36±13.58 0.69±0.14 27±23.21 0.09 (0.00, 0.32) 0.99±0.83 
4 18.43±9.89 0.74±0.19  22.07±19.50 
0.03 
(0.00, 0.16) 1.05±0.59 
 
 
 
Ribavirin 
8 13.50±10.39 
- 
0.86±0.14 
 
P<0.05  
for 0 vs. 8 
 
16.74±13.10 
 
P<0.01  
for 0 vs. 4 
 
P< 0.001  
for 0 vs. 8  
      1 vs. 8 
 
P<0.05  
for 1 vs. 4 
 
0.01 
(0.00, 0.11) 
 
P<0.05  
for 0 vs. 8  
      1 vs. 4 
 
P<0.01  
for 1 vs. 8 
 
1.13±0.92 
- 
0 31.50±2.65 0.65±0.06 22.58±19.71 0.15 (0.00, 0.42) 0.86±0.29 
1 24.25±6.02 0.85±0.05 11.65±10.31 0.04 (0.00, 0.16) 1.09±1.05 
2 21.50±4.51 0.87±0.10 4.85±3.98 0.02 (0.00, 0.09) 0.98±0.10 
 
 
 
CAF 
4 14.75±4.19 
 
 
P<0.01 
for 0 vs. 4
 
0.93±0.06 
 
P<0.01 
for 0 vs. 1  
      0 vs. 2 
 
P< 0.001  
for 0 vs. 4  
      1 vs. 4 
 
2.93±1.72 
 
P<0.001 
 for 0 vs. 1, 
       0 vs. 2, 
       0 vs. 4, 
       1 vs. 4 
P<0.01  
for 1 vs. 2 
 
0.01 
(0.00, 0.07) 
 
 
P<0.001  
for 0 vs. 1,     
      0 vs. 2  
      0 vs. 4 
 
1.04±0.30 
 
  
P<0.05  
for 0 vs. 1 
 
0 22.43±5.48 0.63±0.11 19.30±16.57 0.15 (0.00, 0.42) 0.86±0.31 
16 26.25±6.24 0.62±0.20 19.59 (0.00,40.33) 
0.18 
(0.00, 0.52) 
0.97 
(0.00, 2.10) 
32 25.00±8.45 0.56±0.16 22.74±18.71 0.15 (0.00, 0.43) 
 
0.85±0.39 
 
 
Amantadine 
64 25.75±11.32 
- 
 
0.70±0.08 
- 
 
19.24±13.90
- 
 
0.16 
(0.00, 0.47) 
- 
 
0.89±0.36 
- 
- 
 
 
Table 3: Data are reported as mean and standard deviation. Data are processed using the statistical application program ‘Prisma’, in particular through the Bonferroni’s multiple 
comparison test. Results with a P<0.05 were assumed to be significant. The different statistical significances as well, are reported. *: size of FFU is expressed as the number of BDV 
infected cells per FFU. 
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Table 4. Total number of FFU, number of FFU without new infected cells, size* of the FFU, number of new infected cells per FFU and number of  
daughter cells per FFU when Vero cells are incubated with the different concentrations of  Ribavirin, CAF and Amantadine. 
 
 
Vero cell   
 
µM No of FFU  Statistical Significance 
No of FFU 
without new 
infected cells 
Statistical 
Significance Size* of FFU 
Statistical 
Significance 
New infected 
cells per FFU 
Statistical 
Significance 
Daughter 
cells per FFU 
Statistical 
Significance 
0  12.75±12.72 0.30±0.24 
7.40 (0.00, 
15.78) 0.50±0.41 
 
0.47±0.41 
1 8.91 (0.00, 19.22) 0.46±0.24 
8.48 (0.00, 
17.87) 
0.37(0.00, 
0.77) 0.56±0.42 
4 10.83±10.32 0.37±0.21  7.95±7.04 0.44±0.41 0.47±0.41 
 
 
 
Ribavirin 
8 9.75±9.96 
- 
0.48±0.28 
- 
6.80 
(0.00,13.96)
- 
0.44±0.41 
 
 
P<0.05  
for 0 vs. 1 
 
 
0.65 
(0.00, 2.21) 
- 
0 15.83±10.98 0.38±0.16 7.48±6.48 0.49±0.42 0.54±0.44 
1 4.17±1.17 0.90±0.15 1.24±0.52 0.06 (0.00, 0.28) 0.94±0.22 
2  3.40±0.90 0.92±0.20 1.37±1.17 0.04 (0.00, 0.19) 0.96±0.15 
 
 
 
CAF 
4 5.67±1.03 
 
 
P<0.05  
for 0 vs. 1, 
      0 vs. 2,  
      0 vs. 4 
 0.94±0.11 
 
 
P<0.001  
for 0 vs. 1, 
      0 vs. 2,  
      0 vs. 4 
 
1.06±0.23 
 
  
P<0.001  
for 0 vs. 1, 
      0 vs. 2,  
      0 vs. 4 
 0.09 (0.00, 
0.38) 
 
  
 
P<0.001  
for 0 vs.1,  
      0 vs. 2,  
      0 vs. 4 
0.97±0.17 
 
 
  
P<0.001  
for 0 vs. 1,  
      0 vs. 2,  
      0 vs. 4 
 
0 20.00±15.68 0.39±0.20 8.30±6.90 0.45±0.42 0.56±0.42 
16 43.50±4.95 0.44±0.09 5.47±4.71 0.31 (0.00, 0.69) 0.67±0.39 
32 28.67±15.28  0.66±0.32 
7.04  
(0.00,14.24) 
0.28 
(0.00, 0.64) 
 
0.70±0.38 
 
 
 
Amantadine 
64 29.00±13.00 
- 
 
0.44±0.20 
- 
 
3.75±3.09 
 
 
P<0.01  
for 0 vs. 16 
  
P<0.001  
for 0 vs. 64 
 
0.31 
(0.00, 0.70) 
 
 
  
P<0.05  
for 0 vs. 16, 
      0 vs. 64 
  
P<0.01  
for 0 vs. 32 
 
0.90 
(0.00, 3.02) 
- 
 
 
Table 4: Data are reported as mean and standard deviation. Data are processed using the statistical application program ‘Prisma’, in particular through the Bonferroni’s multiple 
comparison test. Results with a P<0.05 were assumed to be significant. The different statistical significances as well, are reported. *: size of FFU is expressed as the number of BDV 
infected cells per FFU. 
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